Routine

Secondary hypogammaglobulinaemia (drug-induced)

Low immunoglobulins from medication or protein loss · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Secondary hypogammaglobulinaemia results from drugs (rituximab and other B-cell therapies, anti-epileptics, corticosteroids), protein loss (nephrotic syndrome, protein-losing enteropathy) or malignancy, and can cause recurrent infection. It must be distinguished from primary immunodeficiency and managed by addressing the cause and, where needed, immunoglobulin replacement.

Red flags

  • Recurrent or severe bacterial infections
  • Persistently low IgG months after rituximab
  • Nephrotic-range proteinuria
  • Features of underlying myeloma or lymphoma
  • Neutropenia compounding infection risk

Assessment

Differential diagnosis

  • Common variable immunodeficiency (primary)
  • B-cell-depleting therapy effect (rituximab)
  • Protein-losing states (nephrotic syndrome, enteropathy)
  • Haematological malignancy (myeloma, CLL, lymphoma)
  • Anti-epileptic or immunosuppressant drug effect

Investigations

  • Serum immunoglobulins and electrophoresis / free light chains
  • Medication review (rituximab, anticonvulsants, steroids, mycophenolate)
  • Urine protein and albumin (nephrotic range loss)
  • FBC and blood film; bone marrow if malignancy suspected
  • Vaccine responses and lymphocyte subsets to assess function

Management

  • Identify and quantify the degree of immunoglobulin reduction
  • Review and, where possible, withdraw or substitute the offending drug
  • Investigate for protein loss and underlying haematological malignancy
  • Treat acute infections promptly with appropriate antibiotics
  • Assess functional antibody responses to decide on replacement
  • Start immunoglobulin replacement if recurrent serious infection despite addressing the cause
  • Vaccinate (inactivated vaccines) when immune function permits and avoid live vaccines if significantly immunosuppressed
  • Monitor immunoglobulin recovery after drug cessation and liaise with immunology

Drugs & doses

Immunoglobulin replacement — IVIG 0.4-0.6 g/kg every 3-4 weeks (or subcutaneous equivalent) if recurrent serious infection
Co-amoxiclav — 625 mg orally three times daily for acute bacterial infection
Prophylactic co-trimoxazole — 480-960 mg orally daily in selected immunosuppressed patients
Pneumococcal and influenza (inactivated) vaccines — per schedule when immune function allows

Disposition

Manage with immunology input; treat the underlying cause and provide replacement or prophylaxis as needed, with admission for serious infection.

Complications & pitfalls

  • Recurrent respiratory infections and bronchiectasis
  • Severe or opportunistic infection
  • Persistent hypogammaglobulinaemia after B-cell therapy
  • Delay in recognising underlying malignancy
  • Vaccine failure

Exam pearls

  • Always review the drug chart — rituximab, anticonvulsants and steroids are common culprits
  • Distinguish from primary immunodeficiency by history and recovery after removing the cause
  • Check for protein loss and occult malignancy in unexplained low immunoglobulins
  • Replacement is warranted when serious infections recur despite treating the cause

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.